Peer-reviewed veterinary case report
Photodynamic therapy safety and results for cat skin cancer
By Buchholz, Julia et al.·Published in Journal of veterinary internal medicine·2007·Vetsuisse-Faculty of the University of Zurich·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Photodynamic therapy of feline cutaneous squamous cell carcinoma using a newly developed liposomal photosensitizer: preliminary results concerning drug safety and efficacy.
- Species:
- cat
Plain-English summary
Eighteen cats with skin tumors called squamous cell carcinomas were treated with a new light-based therapy using a special liposomal photosensitizer. This treatment was found to be safe, with only mild local reactions like redness and swelling in a few cats. Remarkably, all the cats responded well to the therapy, achieving complete tumor removal, and 75% maintained control over their tumors for a year. However, about 20% of the cats experienced a recurrence of their tumors after an average of about 172 days. Overall, this new treatment option shows promise for managing skin tumors in cats.
People also search for: cat skin tumor treatment · feline squamous cell carcinoma therapy · photodynamic therapy for cats
Abstract
BACKGROUND: Squamous cell carcinomas are common skin tumors in cats. We investigated photodynamic therapy (PDT) using a new liposomal photosensitizer as a minimally invasive, effective treatment that can be easily performed while achieving good cosmetic results. AIM: The goal of this study was to assess and describe possible toxicities using a liposomal formulation of the photosensitizer meta-(Tetrahydroxyphenyl)Chlorin (m-THPC) and investigate if favorable pharmacokinetics translate into favorable tumor response and control. ANIMALS: Eighteen client-owned cats with 20 spontaneous cutaneous squamous cell carcinomas were included in the study. METHODS: PDT was performed using a new, liposomal formulation of the photosensitizer. Toxicity, tumor response, and tumor control were evaluated retrospectively. RESULTS: No general adverse effects were observed in cats treated with the new liposomal formulation. Mild local toxicity such as erythema and edema were seen in 15% of the patients. All cats responded to therapy, with a complete response rate of 100%. The overall 1-year control rate was 75%. The tumor recurrence rate was 20% with a median time to recurrence of 172.25 +/-87.1) days. CONCLUSIONS AND CLINICAL IMPORTANCE: A new liposomal photosensitizer was successfully used for squamous cell carcinoma in cats and was well tolerated. There were no systemic adverse effects observed with the liposomal formulation. The favorable pharmacokinetics of the liposomal drug resulted in a favorable tumor response.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17708398/